Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
← catalyst calendarNCT07230834 · readout in 684 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
54estimated
Sites
9
Countries
Georgia, Puerto Rico, Romania +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-19 | actual | When the study began enrolling |
| Primary completion | 2028-07-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-03 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Geographic Atrophy (GA)
Intervention
- Drug: Pozelimab — also filed as REGN3918
Primary outcomes
what the primary-completion date above is the date OFOccurrence of ocular Treatment-Emergent Adverse Event (TEAEs) in the study eye
measured Through week 8
Occurrence of ocular TEAEs in the study eye
measured Through week 16
Occurrence of systemic TEAEs
measured Through week 8
Occurrence of systemic TEAEs
measured Through week 16
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed